Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2017-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1164/rccm.201606-1226PPPMID 27627135PMCID PMC5803657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA Damage and Pulmonary Hypertension

  2016cited by this paper
• HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.

  2016cited by this paper
• Molecular pathogenesis and current pathology of pulmonary hypertension

  2016cited by this paper
• MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer?

  2016cited by this paper
• Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies

  2016cited by this paper
• Up‐regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension

  2016cited by this paper
• Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.

  2016cited by this paper
• The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

  2016cited by this paper
• Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension.

  2016cited by this paper
• Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.

  2016cited by this paper
• Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

  2015cited by this paper
• Mechanism of Activation-Induced Downregulation of Mitofusin 2 in Human Peripheral Blood T Cells

  2015cited by this paper
• Pro-apoptotic and anti-proliferative effects of mitofusin-2 via PI3K/Akt signaling in breast cancer cells.

  2015cited by this paper
• Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension.

  2015cited by this paper
• Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.

  2015cited by this paper
• Mitochondrial dynamics in pulmonary arterial hypertension

  2015cited by this paper
• Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)

  2015cited by this paper
• Endothelial chromosome 13 deletion in congenital heart disease-associated pulmonary arterial hypertension dysregulates SMAD9 signaling.

  2015cited by this paper
• Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats

  2015cited by this paper
• Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

  2015cited by this paper
• Mitofusin 2 ameliorates aortic remodeling by suppressing ras/raf/ERK pathway and regulating mitochondrial function in vascular smooth muscle cells.

  2015cited by this paper
• Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

  2015cited by this paper
• Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.

  2015cited by this paper
• Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

  2015cited by this paper
• Neonatal pulmonary arterial hypertension and Noonan syndrome: Two fatal cases with a specific RAF1 mutation

  2015cited by this paper
• Novel and emerging therapies for pulmonary hypertension.

  2014cited by this paper
• Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension.

  2014cited by this paper
• The metabolic basis of pulmonary arterial hypertension.

  2014cited by this paper
• Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension

  2014cited by this paper
• Mammalian Target of Rapamycin Complex 2 (mTORC2) Coordinates Pulmonary Artery Smooth Muscle Cell Metabolism, Proliferation, and Survival in Pulmonary Arterial Hypertension

  2014cited by this paper
• Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

  2014cited by this paper
• Role for DNA Damage Signaling in Pulmonary Arterial Hypertension

  2014cited by this paper
• Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

  2014cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• Role for Telomerase in Pulmonary Hypertension

  2014cited by this paper
• Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α.

  2014cited by this paper
• Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.

  2014cited by this paper
• Role of mitofusin 2 (Mfn2) in controlling cellular proliferation

  2014cited by this paper
• The Right Ventricle in Pulmonary Arterial Hypertension: Disorders of Metabolism, Angiogenesis and Adrenergic Signaling in Right Ventricular Failure

  2014cited by this paper
• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  2014cited by this paper
• Everolimus in Patients with Severe Pulmonary Hypertension: A Safety and Efficacy Pilot Trial

  2013cited by this paper
• The Hippo pathway and human cancer

  2013cited by this paper
• FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.

  2013cited by this paper
• Selective Inactivation of PTEN in Smooth Muscle Cells Synergizes With Hypoxia to Induce Severe Pulmonary Hypertension

  2013cited by this paper
• Sevoflurane Preconditioning Attenuates Myocardial Ischemia/Reperfusion Injury via Caveolin-3–Dependent Cyclooxygenase-2 Inhibition

  2013cited by this paper
• Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling

  2013cited by this paper
• Forkhead box proteins: tuning forks for transcriptional harmony.

  2013cited by this paper
• The detection and implication of genome instability in cancer

  2013cited by this paper
• Pathogenesis of pulmonary arterial hypertension: lessons from cancer

  2013cited by this paper
• Harvest of pulmonary artery endothelial cells from patients undergoing right heart catheterization.

  2013cited by this paper
• Inhibition of Phosphatidylinositol 3-kinase/Akt Signaling Attenuates Hypoxia-induced Pulmonary Artery Remodeling and Suppresses CREB Depletion in Arterial Smooth Muscle Cells

  2013cited by this paper
• Relevant issues in the pathology and pathobiology of pulmonary hypertension.

  2013cited by this paper
• Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.

  2013cited by this paper
• Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

  2013cited by this paper
• Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)

  2013cited by this paper
• Heterogeneity in Lung 18FDG Uptake in Pulmonary Arterial Hypertension: Potential of Dynamic 18FDG Positron Emission Tomography With Kinetic Analysis as a Bridging Biomarker for Pulmonary Vascular Remodeling Targeted Treatments

  2013cited by this paper
• The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

  2012cited by this paper
• Pathobiology of pulmonary arterial hypertension and right ventricular failure

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis

  2012cited by this paper
• Retracted: Mice lacking the Raf‐1 kinase inhibitor protein exhibit exaggerated hypoxia‐induced pulmonary hypertension

  2011cited by this paper
• Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities.

  2011cited by this paper
• A Critical Role for the Protein Apoptosis Repressor With Caspase Recruitment Domain in Hypoxia-Induced Pulmonary Hypertension

  2011cited by this paper
• Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension.

  2011cited by this paper
• Mechanisms of disease: pulmonary arterial hypertension

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Dysregulation of PTEN in Cardiopulmonary Vascular Remodeling Induced by Pulmonary Hypertension

  2011cited by this paper
• mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia

  2011cited by this paper
• The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension.

  2011cited by this paper
• Signal Transducers and Activators of Transcription-3/Pim1 Axis Plays a Critical Role in the Pathogenesis of Human Pulmonary Arterial Hypertension

  2011cited by this paper
• p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice.

  2011cited by this paper
• Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed.

  2010cited by this paper
• Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

  2010cited by this paper
• Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.

  2010cited by this paper
• A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

  2010cited by this paper
• Roles for growth factors in cancer progression.

  2010cited by this paper
• Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

  2010cited by this paper
• Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

  2010cited by this paper
• Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.

  2010cited by this paper
• Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

  2010cited by this paper
• mTOR: from growth signal integration to cancer, diabetes and ageing

  2010cited by this paper
• Nitrite Potently Inhibits Hypoxic and Inflammatory Pulmonary Arterial Hypertension and Smooth Muscle Proliferation via Xanthine Oxidoreductase–Dependent Nitric Oxide Generation

  2010cited by this paper
• Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.

  2009cited by this paper
• NOTCH3 SIGNALING IS REQUIRED FOR THE DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION

  2009cited by this paper
• A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension

  2009cited by this paper
• TGFbeta in Cancer.

  2008cited by this paper
• Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

  2008cited by this paper
• Molecular pathogenesis of pulmonary arterial hypertension.

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Rational targeting of Notch signaling in cancer

  2008cited by this paper
• The cancer paradigm of severe pulmonary arterial hypertension.

  2008cited by this paper
• Bcl-2 family proteins and cancer

  2008cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

  2008cited by this paper
• Targeted Deletion of PTEN in Smooth Muscle Cells Results in Vascular Remodeling and Recruitment of Progenitor Cells Through Induction of Stromal Cell–Derived Factor-1&agr;

  2008cited by this paper
• Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer.

  2008cited by this paper
• Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.

  2007cited by this paper
• MAP kinase signalling pathways in cancer

  2007cited by this paper
• The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted

  2007cited by this paper

• Identification of circulating microRNA biomarkers in pulmonary hypertension of group 2 for early detection.

  2026cites this paper
• Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.

  2026cites this paper
• Methamphetamine‐Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management

  2026cites this paper
• [Silencing DDX17 inhibits proliferation and migration of pulmonary arterial smooth muscle cells in vitro by decreasing mTORC1 activity].

  2025cites this paper
• The Role of Toll-like Receptors and Viral Infections in the Pathogenesis and Progression of Pulmonary Arterial Hypertension—A Narrative Review

  2025cites this paper
• Lactate dehydrogenase-induced DNA Topoisomerase 1 is a novel regulator of smooth muscle cell proliferation and remodeling in pulmonary arterial hypertension

  2025cites this paper
• The underexplored pulmonary toxicity of pyrrolizidine alkaloids: Emerging hazard from food contamination.

  2025cites this paper
• BMP10 in Cardiovascular Disease: From Pathogenesis to Therapeutic Strategies.

  2025cites this paper
• Exploratory Study of Prognostic Plasma Biomarkers in Patients with Pulmonary Arterial Hypertension

  2025cites this paper
• Opposing roles for myeloid and smooth muscle cell STING in pulmonary hypertension

  2025cites this paper
• Identification of a PANoptosis-related gene signature reveals therapeutic potential of SFRP2 in pulmonary arterial hypertension

  2025cites this paper
• Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies

  2025cites this paper
• NSD2 mediated H3K36me2 promotes pulmonary arterial hypertension by recruiting FOLR1 and metabolism reprogramming.

  2025cites this paper
• Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies

  2025cites this paper
• Antiproliferative therapies in pulmonary arterial hypertension

  2025cites this paper
• Multidimensional study on mitochondrial dysfunction in pulmonary hypertension

  2025cites this paper
• Unraveling the Mfn2-Warburg effect nexus: a therapeutic strategy to combat pulmonary arterial hypertension arising from catch-up growth after IUGR

  2024cites this paper
• NCAM1 modulates the proliferation and migration of pulmonary arterial smooth muscle cells in pulmonary hypertension

  2024cites this paper
• Vitamin D receptor and its antiproliferative effect in human pulmonary arterial hypertension

  2024cites this paper
• Study on the mechanism of echinacoside in preventing and treating hypoxic pulmonary hypertension based on proteomic analyses

  2024cites this paper
• The causes of pulmonary hypertension and the benefits of aerobic exercise for pulmonary hypertension from an integrated perspective

  2024cites this paper
• SOX9 promotes hypoxic pulmonary hypertension through stabilization of DPP4 in pulmonary artery smooth muscle cells.

  2024cites this paper
• Identification of SNHG11 as a Therapeutic Target in Pulmonary Hypertension.

  2024cites this paper
• Non-invasive surrogate markers of pulmonary hypertension are associated with poor survival in patients with cancer

  2024cites this paper
• DGP-Kongress 2024 – „Key Takeaways aus Keynote Lectures“: Pneumologie erblühe: selbstbewusst, zukunftsorientiert und präventiv orientiert

  2024cites this paper
• Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights from Comprehensive Multicenter Preclinical Studies

  2024cites this paper
• The diverging roles of insulin-like growth factor binding proteins in pulmonary arterial hypertension.

  2024cites this paper
• Carotid Baroreceptor Stimulation Improves Pulmonary Arterial Remodeling and Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

  2024cites this paper
• Non‐canonical IKB kinases regulate YAP/TAZ and pathological vascular remodeling behaviors in pulmonary artery smooth muscle cells

  2024cites this paper
• Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human.

  2024cites this paper
• Mendelian Randomization in Pulmonary Arterial Hypertension: Unveiling Early Insights With Promise for Future Discoveries

  2024cites this paper
• Activation of the p62‐Keap1‐Nrf2 pathway improves pulmonary arterial hypertension in MCT‐induced rats by inhibiting autophagy

  2024cites this paper
• Hypusine Signaling Promotes Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

  2024cites this paper
• Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation

  2023influential citation
• Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension.

  2023cites this paper
• PAI-1 Deficiency Drives Pulmonary Vascular Smooth Muscle Remodeling and Pulmonary Hypertension

  2023cites this paper
• Polo-like kinase 1 promotes pulmonary hypertension

  2023cites this paper
• Endothelial FIS1 DeSUMOylation Protects Against Hypoxic Pulmonary Hypertension

  2023cites this paper
• Evidence for Hypoxia-Induced Shift in ATP Production from Glycolysis to Mitochondrial Respiration in Pulmonary Artery Smooth Muscle Cells in Pulmonary Arterial Hypertension

  2023cites this paper
• P53 in Vascular Remodeling: The Potential for Targeting in Atherosclerosis

  2023cites this paper
• Insights into Endothelin Receptors in Pulmonary Hypertension

  2023influential citation
• Too hot? Too cold? Wnt signalling in pulmonary arterial hypertension: can we treat it “just right”?

  2023cites this paper
• Research progress of PDGF-BB/ERK/HIF-1α signaling pathway in hypoxic pulmonary hypertension

  2023cites this paper
• GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension

  2023cites this paper
• Mitochondria in Health, Disease, and Ageing.

  2023cites this paper
• Single Nucleotide Polymorphism rs9277336 Controls the Nuclear Alpha Actinin 4‐Human Leukocyte Antigen‐DPA1 Axis and Pulmonary Endothelial Pathophenotypes in Pulmonary Arterial Hypertension

  2023cites this paper
• Kaempferol ameliorates pulmonary vascular remodeling in chronic hypoxia-induced pulmonary hypertension rats via regulating Akt-GSK3β-cyclin axis.

  2023cites this paper
• Activation of PPAR-γ prevents TERT-mediated pulmonary vascular remodeling in MCT-induced pulmonary hypertension

  2023cites this paper
• Histone Methyl Transferase G9a/GLP—A Novel Avenue in Pulmonary Arterial Hypertension Treatment?

  2023cites this paper
• Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models.

  2023cites this paper
• G9a/GLP Targeting Ameliorates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

  2023cites this paper
• Proteasome Inhibitors Decrease the Viability of Pulmonary Arterial Smooth Muscle Cells by Restoring Mitofusin-2 Expression under Hypoxic Conditions

  2022cites this paper
• Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival

  2022cites this paper
• Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension

  2022cites this paper
• The clinical impact of COVID-19 on patients with cancer in British Columbia: An observational study

  2022cites this paper
• MonOrail to Cure? Targeting Orai1 to Reverse Pulmonary Arterial Hypertension.

  2022cites this paper
• Akt-Dependent Glycolysis-Driven Lipogenesis Supports Proliferation and Survival of Human Pulmonary Arterial Smooth Muscle Cells in Pulmonary Hypertension

  2022cites this paper
• Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension

  2022cites this paper
• Stem Cell–derived Nanovesicles for the Treatment of Pulmonary Hypertension: Are We There Yet?

  2022cites this paper
• Inhibition of KIF23 Alleviates IPAH by Targeting Pyroptosis and Proliferation of PASMCs

  2022cites this paper
• BMPR2 Editing in Fibroblast NIH3T3 using CRISPR/Cas9 Affecting BMPR2 mRNA Expression and Proliferation

  2022cites this paper
• Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells

  2021cites this paper
• Genetic Delivery and Gene Therapy in Pulmonary Hypertension

  2021cites this paper
• Glucose-6 Phosphate dehydrogenase deficiency contributes to metabolic abnormality and pulmonary hypertension.

  2021cites this paper
• Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension

  2021cites this paper
• Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19

  2021cites this paper
• Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension

  2021cites this paper
• Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension.

  2021cites this paper
• Identification of a potentially novel LncRNA-miRNA-mRNA competing endogenous RNA network in pulmonary arterial hypertension via integrated bioinformatic analysis.

  2021cites this paper
• Site-specific delivery of inhalable antiangiogenic liposomal dry powder inhaler technology ameliorates experimental pulmonary hypertension

  2021cites this paper
• Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension

  2021cites this paper
• Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9

  2021cites this paper
• Long-Term Effect of a Vaccine Targeting Endothelin-1 Receptor Type A in Pulmonary Arterial Hypertension

  2021influential citation
• Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?

  2021cites this paper
• Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers

  2021cites this paper
• Notch2 Suppression Mimicking Changes in Human Pulmonary Hypertension Modulates Notch1 and Promotes Endothelial Cell Proliferation.

  2021cites this paper
• Heat shock protein 70 attenuates hypoxia-induced apoptosis of pulmonary microvascular endothelial cells isolated from neonatal rats

  2021cites this paper
• TSC2-extracellular matrix crosstalk controls pulmonary vascular proliferation and pulmonary hypertension

  2021cites this paper
• Novel Pharmacological Targets for Pulmonary Arterial Hypertension.

  2021cites this paper
• Adenylate Kinase 4—A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1α Signaling Pathways

  2021cites this paper
• Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension

  2021cites this paper
• LAMC2 promotes the proliferation of cancer cells and induce infiltration of macrophages in non-small cell lung cancer

  2021cites this paper
• Non-invasive Surrogate Markers of PH are Associated with Poor Survival in Lung Cancer Patients.

  2021cites this paper
• DDDT_A_297500 1653..1666

  2021cites this paper
• A Plot TWIST in Pulmonary Arterial Hypertension

  2020cites this paper
• Icotinib attenuates monocrotaline-induced pulmonary hypertension by preventing pulmonary arterial smooth muscle cell dysfunction.

  2020cites this paper
• Hypoxia-inducible factor signaling in pulmonary hypertension.

  2020cites this paper
• Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in PAH.

  2020cites this paper
• PULMONARY, SLEEP, AND CRITICAL CARE UPDATE Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019

  2020cites this paper
• Assessing the Cancer Hypothesis of Pulmonary Arterial Hypertension: The Devil is in the Detail.

  2020cites this paper
• PDGF mediates pulmonary arterial smooth muscle cell proliferation and migration by regulating NFATc2

  2020cites this paper
• Perspective: Pathobiological paradigms in pulmonary hypertension, time for reappraisal.

  2020cites this paper
• Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk

  2020cites this paper
• Differential effects of integrin-linked kinase inhibitor Cpd22 on severe pulmonary hypertension in male and female rats

  2020cites this paper
• Mural Cell SDF1 Signaling is Associated with the Pathogenesis of Pulmonary Arterial Hypertension.

  2020cites this paper
• The Hallmarks of Severe Pulmonary Arterial Hypertension: The Cancer Hypothesis - Ten years later.

  2020cites this paper
• mTORC1 in Pulmonary Arterial Hypertension. At the Crossroads between Vasoconstriction and Vascular Remodeling?

  2020cites this paper
• Zooming into Cellular and Molecular Heterogeneity of Pulmonary Hypertension. What More Single-Cell Omics Can Offer

  2020cites this paper
• Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.

  2020cites this paper
• In Defense of the Nucleus: NUDT1 and Oxidative DNA Damage in Pulmonary Arterial Hypertension

  2020cites this paper